Final Results Of Home-made Sirolimus-eluting Stent Versus Bare Metal Stent In Acute Myocardial Infarction

ObjectiveTo assess the safety and efficacy of home-made rapamycin eluting stent (Firebird stent) versus bare metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI).Materials and MethodsEnrolled patients with STEMI during one year period were randomized to undergo implantation of Firebird stent or BMS, and subsequently underwent clinical and angiographic follow-up studies. The primary endpoint of the present study is in-lesion late lumen loss (LLL) at 6 months, and secondary endpoint includes stent thrombosis and major adverse cardiac events at 6 months.ResultsDuring one year period, 56 patients were randomized into the Firebird stent group (56 patients with an average age of 57.78 years old) or the BMS group (55 patients with an average age of 59.69 years old). Six-month angiographic follow-ups were available in 64.3% and 63.7% of patients assigned to Firebird stent and BMS, respectively. At 6-month follow-up, mortality, target vessel revascularization and MAEC in the Firebird stent group were 3.6% versus3.6% in the BMS group, 10.7% versus 30.9% and 16.1% versus 32.7%. Sub-acute thrombosis occurred in 1 patient in both groups. The mean LLL were 0.18mm in the Firebird stent group versus 0.72mm in the BMS group. ConclusionsImplantation of home-made rapamycin eluting stent (Firebird stent) for STEMI dramatically reduced MACE at 6 months compared to BMS.This reduction was driven by a decrease in the rate of TVR.At the same time,there was no significant difference between the two groups in the rate of acute/sub-acute stent thrombosis.Among STEMI patients,the use of Firebird is safe and effective.